Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ridgeback Biotherapeutics LP

https://www.ridgebackbio.com/

Latest From Ridgeback Biotherapeutics LP

Merck Revenue Soars, Setting High Bar For Future Growth

With pharma sales up 13% in Q3, questions mount about investments in its pipeline to diversify beyond Keytruda and keep the momentum going after its top seller faces biosimilars in 2028. 

Sales & Earnings Deals

Asia Deal Watch: Astellas Seeks Pantherna’s Assistance On mRNA-Based Regenerative Medicine

Plus deals involving OliPass/Vanda, Simcere/Almirall, Sinopharm/Merck & Co., Jiuzhou/Sandoz, Zai Lab/Seagen, Sciwind/SynderK, Hansoh/KiOmed.

Deal Watch Business Strategies

Finance Watch: SPAC Deals Emerge As IPO Market Goes Quiet Again

Public Company Edition: Direct Biologics, YishengBio and Estrella Biopharma will go public by merging with special purpose acquisition corporations. Also, Vir lands a government contract worth up to $1bn, Idorsia raises CHF164m ($167.4m) in a real estate deal and Adamis reviews alternatives.

Financing Business Strategies

The COVID-19 Market: Keeping Up With The Changing Landscape

Some products are still going strong, while others that once generated blockbuster revenues have faded away, as companies develop next-generation antivirals and vaccines.

Coronavirus COVID-19 Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
  • Pharmaceuticals
UsernamePublicRestriction

Register